BioClinica, Inc. Signs Five-Year Agreement for Optimizer Technology with Top Ten Global Pharmaceutical Company

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations. BioClinica Optimizer was selected for its flexibility to simulate and optimize large-scale, complex clinical trials while remaining cost effective for smaller, early phase studies.

MORE ON THIS TOPIC